Buy the rumor, sell the news. I'm not surprised your stock went down. It sounds like it's just a temporary price move, if it can gain FDA approval.
Let the traders and the impatient and the risk averse have their scraps. If Blarcamesine works better than Aricept and is easier to administer than Lecanemab and is safer and less expensive than Aduhelm, it should be approved.
The value of Blarcamesine approval isn't going to be realized for 12-18 months because it'll take that long to get the manufacturing and distribution operations running in sync at full efficiency if Dr. Missling decides to go at it alone.
Those who want to short the stock or wait for more information should have time because Anavex is in a holding pattern for the time being. The risk, of course, is that partnership news could be announced at any moment. We know of one meeting Anavex allegedly already had last month with an investment bank. My guess is there have been other meetings with other firms that we haven't heard about. Where there's smoke there's usually fire.
Market Data 
Markets 
AI
